Holen Sie sich die Stockscreener-App
30.48
0.43%
0.13
Handel nachbörslich:
30.31
-0.17
-0.56%
Schlusskurs vom Vortag:
$30.35
Offen:
$30.44
24-Stunden-Volumen:
1.02M
Relative Volume:
1.88
Marktkapitalisierung:
$1.42B
Einnahmen:
$723.55M
Nettoeinkommen (Verlust:
$157.72M
KGV:
10.16
EPS:
3
Netto-Cashflow:
$170.15M
1W Leistung:
+46.40%
1M Leistung:
+40.72%
6M Leistung:
-3.97%
1J Leistung:
-30.03%
1-Tages-Spanne:
$30.00
$31.23
1-Wochen-Bereich:
$20.70
$31.23
52-Wochen-Spanne:
$20.39
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Vergleichen Sie AMPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
30.48 | 1.41B | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Amphastar Pharmaceuticals (NASDAQ:AMPH) Raised to "Buy" at Needham & Company LLC - MarketBeat
Amphastar and Anji make licence agreement for three new peptides - Yahoo Finance
Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights - TipRanks
Amphastar Pharmaceuticals Gets Upgrade to Buy at Needham on AMP-002 Approval - AInvest
Amphastar Pharmaceuticals Upgraded to Buy by Needham Analyst - AInvest
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals Secures FDA Approval for Iron Sucrose Injection, Sets Sights on Major Sales Momentum - AInvest
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
Amphastar raised to Buy at Needham on iron sucrose injection approval - Seeking Alpha
Amphastar stock gains after licensing deal for three peptide therapies By Investing.com - Investing.com Canada
Needham upgrades Amphastar Pharmaceuticals stock to Buy on iron sucrose approval - Investing.com Canada
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Amphastar licenses three peptide therapies in oncology, ophthalmology deal By Investing.com - Investing.com South Africa
Amphastar Pharmaceuticals Enters Strategic Licensing Agreement - TipRanks
Amphastar gets FDA nod for generic iron sucrose injection - MSN
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - ACCESS Newswire
Amphastar's $453M Breakthrough: Exclusive Rights to Revolutionary Cancer and Eye Disease Peptide Therapies - Stock Titan
AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones - Yahoo Finance
Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline - insights.citeline.com
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Amphastar Pharmaceuticals (AMPH) stock surges 10.4% on FDA approval for generic Iron Sucrose Injection treatment for iron deficiency anemia. - AInvest
Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today - FinancialContent
FDA OKs Generic Iron Sucrose for CKD Anemia - Conexiant
Amphastar Soars 14.36% on FDA Approval: A Game-Changer or Fleeting Rally? - AInvest
Amphastar stock rises after FDA approves generic iron sucrose injection By Investing.com - Investing.com Canada
FDA approves Amphastar’s iron sucrose injection for anemia treatment By Investing.com - Investing.com Australia
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - ACCESS Newswire
18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 12.1%Here's Why - MarketBeat
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - MSN
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
Interpace Biosciences Earnings Drop - AOL.com
Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... By GuruFocus - Investing.com Canada
Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock - MarketBeat
Amphastar 2025 Q2 Earnings Net Income Falls 18.2% Amid Revenue Decline - AInvest
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Piper Sandler lowers Amphastar Pharmaceuticals stock price target on competitive headwinds - Investing.com Canada
Earnings call transcript: Amphastar Q2 2025 beats EPS forecast, stock rises - Investing.com Canada
Amphastar August 2025 presentation slides: long-term growth strategy faces near-term headwinds - Investing.com Canada
Amphastar Pharmaceuticals Topped Earnings And Is Doubling Down At Home - Finimize
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6% - Yahoo Finance
Atea (AVIR) Q2 Loss Narrows 8% - AOL.com
Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures - MSN
Amphastar's Q2 2025: Unpacking Contradictions in BAQSIMI Growth, Manufacturing Capacity, and FDA Approvals - AInvest
Amphastar Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights - TipRanks
Amphastar Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar (AMPH) Q2 2025 Earnings Call Transcript - AOL.com
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):